Trial intelligence / Profile preview

Combined LT4 + LT3 versus LT4 for TSH control in advanced thyroid cancer on TKI therapy

2026-526113-28-00Phase 4Authorised

Sponsor: CEINGE-Biotecnologie Avanzate
Start: Jun 2026
Modality: Small Molecules
Countries: 1

Overview

Phase 4, randomised trial in thyroid cancer and hypothyroidism comparing Levothyroxine monotherapy with Levothyroxine + liothyronine combination (2 arms). Planned start Jun 2026; status: authorised.

Drugs

levothyroxine sodiumliothyronine

Conditions

thyroid cancerhypothyroidism

Beyond the preview

Go deeper on 2026-526113-28-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2026-526113-28-00.